Safety considerations when using non-ergot dopamine agonists to treat Parkinson's disease.

Safety considerations when using non-ergot dopamine agonists to treat Parkinson's disease. Expert Opin Drug Saf. 2020 Sep 01;: Authors: Stocchi F, Fossati B, Torti M Abstract INTRODUCTION: Non ergot dopamine agonists (NEDA) represent an excellent treatment option for Parkinson's disease (PD) patients, in both early and advanced stages of the disease. The post-marketing phase of NEDA has highlighted, though, the occurrence of important long-term adverse events. AREAS COVERED: This review reports recent updates on NEDA adverse events, analysing neurobiological bases and risk factors of these complications. A literature search has been performed using Medline and reviewing the bibliographies of selected articles. EXPERT OPINION: NEDA represents a very important option in the treatment of PD. Criticisms on their use can be overcome through a better knowledge of these molecules and of the risk factors for adverse events which allow specialists to prevent the occurrence of undesired complications and consent a tailor-based approach. PMID: 32869676 [PubMed - as supplied by publisher]
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research